Related Experiment Videos
Summary
Adriamycin and a cyclophosphamide, vincristine, methotrexate, and 5-fluorouracil (COMF) regimen show promise for mesothelioma chemotherapy. These treatments offer worthwhile remissions, suggesting malignant diffuse mesothelioma may be more responsive than previously thought.
Area of Science:
- Oncology
- Medical Oncology
- Clinical Research
Background:
- Mesothelioma is a rare and aggressive cancer with limited treatment options.
- Evaluating the efficacy of chemotherapy regimens in patients with malignant pleural and peritoneal mesothelioma is crucial.
Observation:
- Six patients with pleural mesothelioma and one with peritoneal mesothelioma were analyzed.
- Patients received either adriamycin or a combination chemotherapy regimen (cyclophosphamide, vincristine, methotrexate, and 5-fluorouracil - COMF).
Findings:
- Complete responses were observed in one patient (19 months) with COMF and two patients (19, 7 months) with adriamycin.
- Partial responses were seen in two patients (3, 7 months) with COMF and three patients (2, 6, 9 months) with adriamycin.
- Survival ranged from 2 to 39 months, with a median of 9 months.
Implications:
- Adriamycin and COMF chemotherapy regimens may induce significant remissions in mesothelioma.
- Malignant diffuse mesothelioma appears to be more responsive to chemotherapy than previously understood, warranting further investigation.